ACZONE (dapsone) by Almirall. Approved for sulfone [epc]. First approved in 2005.
Drug data last refreshed 7h ago · AI intelligence enriched 1w ago
ACZONE (dapsone) is a topical sulfone antibiotic gel approved in 2005 for acne vulgaris and other dermatologic indications. It works through antimicrobial and anti-inflammatory mechanisms characteristic of the sulfone drug class. The product is indicated for topical treatment of acne and related skin conditions.
Approaching loss of exclusivity with modest Part D utilization signals a mature product facing generic competition and potential team contraction.
Sulfone
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
Phototoxicity Test of Dapsone Gel in Healthy Volunteers
Photoallergy Potential of Dapsone Gel in Healthy Volunteers
Dermal Tolerability of Dapsone Gel in Healthy Volunteers
A Study of Dapsone Gel in Females With Skin of Color and Acne Vulgaris
Worked on ACZONE at Almirall? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moACZONE offers limited career growth opportunity given LOE approaching status and zero currently linked job openings. Roles on this product focus on defensive brand management, generic transition planning, and field force optimization rather than expansion or innovation.